| Name | Title | Contact Details |
|---|
New Chapter, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. New Chapter, Inc. is based in Brattleboro, VT. You can find more information on New Chapter, Inc. at www.new-chapter.com
HelixVM is a cutting-edge digital health start-up revolutionizing the way healthcare is delivered. Our goal is to free both physicians and patients from the repetitive and time-consuming aspects of routine care, while simultaneously increasing patient access to care and physician income. We understand that the largest healthcare issue today is the challenge of increasing capacity without increasing providers. That`s why we`ve developed innovative solutions that utilize technology to streamline the treatment process and optimize resource allocation. By harnessing the power of asynchronous medicine and AI, we are able to provide patients with fast and efficient access to care, while also freeing up physician time to focus on more complex and critical cases. At HelixVM, we believe that by empowering patients and providers with the tools they need to deliver and receive high-quality care, we can help to transform the healthcare industry. Whether you`re a physician looking for a more efficient and rewarding way to practice medicine, or a patient seeking convenient and accessible care, we are here to help. Join us on our mission to revolutionize healthcare delivery and improve patient outcomes.
Seton Medical Management is a Mobile, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Tower Health brings together more than 11,000 team members, 2,000 nationally recognized physicians, specialists and providers across 65 convenient locations.